PT2782566T - L-serina para uso no tratamento de distúrbios neurodegenerativos - Google Patents
L-serina para uso no tratamento de distúrbios neurodegenerativosInfo
- Publication number
- PT2782566T PT2782566T PT128515764T PT12851576T PT2782566T PT 2782566 T PT2782566 T PT 2782566T PT 128515764 T PT128515764 T PT 128515764T PT 12851576 T PT12851576 T PT 12851576T PT 2782566 T PT2782566 T PT 2782566T
- Authority
- PT
- Portugal
- Prior art keywords
- disorders
- methods
- neurodegenerative diseases
- treating neurodegenerative
- serine
- Prior art date
Links
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 title 2
- 208000015122 neurodegenerative disease Diseases 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 229960001153 serine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562194P | 2011-11-21 | 2011-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2782566T true PT2782566T (pt) | 2021-03-03 |
Family
ID=48470319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT128515764T PT2782566T (pt) | 2011-11-21 | 2012-11-21 | L-serina para uso no tratamento de distúrbios neurodegenerativos |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20130156846A1 (https=) |
| EP (1) | EP2782566B1 (https=) |
| JP (1) | JP6265908B2 (https=) |
| AU (1) | AU2012340563B2 (https=) |
| CA (1) | CA2855854C (https=) |
| DK (1) | DK2782566T3 (https=) |
| ES (1) | ES2856063T3 (https=) |
| IL (1) | IL232710B (https=) |
| PT (1) | PT2782566T (https=) |
| WO (1) | WO2013078395A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017006748A (es) * | 2014-11-24 | 2017-08-28 | Entrinsic Health Solutions Inc | Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades. |
| US10960076B2 (en) | 2017-01-25 | 2021-03-30 | Church & Dwight Co. Inc. | Gummy dosage forms comprising serine |
| KR20180101242A (ko) | 2017-03-02 | 2018-09-12 | 주식회사 아스트로젠 | 엘세린을 유효성분으로 포함하는 혈뇌장벽 장애의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
| AU2019282362B2 (en) * | 2018-06-08 | 2025-04-03 | The Institute For Ethnomedicine | Method of enhancing glucose levels in the central nervous system |
| KR101952443B1 (ko) * | 2018-08-23 | 2019-02-26 | 주식회사 아스트로젠 | 신규한 마그네슘세리네이트 화합물 및 이의 용도 |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| AU2020334128B2 (en) * | 2019-08-21 | 2025-10-23 | Brain Chemistry Labs | Compositions comprising a metal and L-serine, and uses thereof |
| US12578348B2 (en) * | 2021-02-05 | 2026-03-17 | The Institute For Ethnomedicine | Blood indicators of Alzheimer's disease |
| CN112972458B (zh) * | 2021-03-05 | 2022-10-04 | 北京北科华夏生物医药科技有限公司 | 一种组合物在制备阿尔兹海默症治疗药物中的应用 |
| KR102522508B1 (ko) * | 2022-12-16 | 2023-04-18 | 주식회사 아스트로젠 | 마그네슘-세리네이트의 신규한 결정형 및 이의 제조방법 |
| WO2025014008A1 (ko) * | 2023-07-07 | 2025-01-16 | 주식회사 아스트로젠 | 질환의 치료 방법 |
| KR20250081156A (ko) * | 2023-11-29 | 2025-06-05 | 주식회사 아스트로젠 | L-세린 염산염의 제조 방법 및 이의 용도 |
| CN118303636A (zh) * | 2024-04-12 | 2024-07-09 | 南通大学 | 一种改善帕金森症状的功能性食品 |
| KR20260010331A (ko) * | 2024-07-12 | 2026-01-20 | 주식회사 아스트로젠 | L-세린의 리포좀 제형 및 이의 제조 방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3873722A (en) | 1974-05-31 | 1975-03-25 | Nelson Res & Dev | Method for treating schizophrenia |
| US4000318A (en) * | 1974-08-19 | 1976-12-28 | Commonwealth Scientific And Industrial Research Organization | Amino acid supplements |
| US4491589A (en) * | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| JPS6440453A (en) | 1987-08-05 | 1989-02-10 | Mitsui Toatsu Chemicals | Racemization of optically active serine |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| SE502280C2 (sv) | 1991-12-20 | 1995-09-25 | Bio Swede Ab | Separering av aminosyror, aminosyrabaserad monomer och förfarande för framställning därav samt polymert material och förfarande för framställning därav |
| WO1996015788A1 (en) | 1994-11-23 | 1996-05-30 | G.D. Searle & Co. | Use of amino-isoxazolidone compounds for improvement of implicit memory |
| CA2298795A1 (en) * | 1997-07-28 | 1999-02-04 | The Institute Of Physical And Chemical Research | Agent for protecting central nerve cells and enhancing survival thereof |
| EP1073432B1 (en) | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| US6984484B1 (en) * | 1999-01-19 | 2006-01-10 | The Johns Hopkins University | Mammalian serine racemase |
| JP2002316929A (ja) * | 2001-04-18 | 2002-10-31 | Japan Science & Technology Corp | Ｌ−セリン又はグリシンからなる抗アポトーシス剤 |
| WO2004000297A1 (en) * | 2002-06-19 | 2003-12-31 | N.V. Nutricia | Nutritional or pharmaceutical compositions for increasing the creatine response of organisms |
| JP2004182705A (ja) * | 2002-10-11 | 2004-07-02 | Yasutoshi Koga | ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物 |
| US20050028720A1 (en) * | 2003-08-05 | 2005-02-10 | Bell Adam Warwick | Pop-up device for deterring an attacking animal such as a bear |
| US7256002B2 (en) | 2003-08-12 | 2007-08-14 | The Institute For Ethnomedicine | Screening for neurotoxic amino acid associated with neurological disorders |
| US7148192B2 (en) | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
| FI121915B (fi) | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Koostumus psoriasiksen hoitoon |
| US20080027088A1 (en) | 2004-03-26 | 2008-01-31 | Warner-Lambert Company, Llc | Imidazole-Based Hmg-Coa Reductase Inhibitors |
| CA2583947A1 (en) | 2004-10-12 | 2006-04-20 | Forbes Medi-Tech (Research) Inc. | Compounds and methods of treating insulin resistance and cardiomyopathy |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| US20080058395A1 (en) | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| WO2008118785A2 (en) | 2007-03-23 | 2008-10-02 | Tikvah Therapeutics | Methods for treating depression using immediate-impact treatments and d-cycloserine |
| US20080241121A1 (en) | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
| EP2677319B1 (en) * | 2008-07-09 | 2015-12-30 | The Institute for Ethnomedicine | Antibody for detection of a neurotoxic amino acids associated with neurological disorders |
| WO2010132128A1 (en) * | 2009-05-14 | 2010-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease |
| WO2011104298A1 (en) * | 2010-02-24 | 2011-09-01 | Universität Zürich | Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
-
2012
- 2012-11-21 EP EP12851576.4A patent/EP2782566B1/en active Active
- 2012-11-21 AU AU2012340563A patent/AU2012340563B2/en active Active
- 2012-11-21 CA CA2855854A patent/CA2855854C/en active Active
- 2012-11-21 ES ES12851576T patent/ES2856063T3/es active Active
- 2012-11-21 DK DK12851576.4T patent/DK2782566T3/da active
- 2012-11-21 JP JP2014543579A patent/JP6265908B2/ja active Active
- 2012-11-21 US US13/683,821 patent/US20130156846A1/en not_active Abandoned
- 2012-11-21 PT PT128515764T patent/PT2782566T/pt unknown
- 2012-11-21 WO PCT/US2012/066373 patent/WO2013078395A1/en not_active Ceased
-
2014
- 2014-03-28 US US14/229,624 patent/US11917986B2/en active Active
- 2014-05-20 IL IL232710A patent/IL232710B/en unknown
-
2017
- 2017-10-06 US US15/727,335 patent/US11700840B2/en active Active
-
2021
- 2021-02-02 US US17/165,897 patent/US12295353B2/en active Active
- 2021-07-12 US US17/373,434 patent/US11974551B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL232710A0 (en) | 2014-07-31 |
| US11700840B2 (en) | 2023-07-18 |
| EP2782566A1 (en) | 2014-10-01 |
| EP2782566A4 (en) | 2016-01-13 |
| DK2782566T3 (da) | 2021-02-08 |
| US20140212893A1 (en) | 2014-07-31 |
| US20210153483A1 (en) | 2021-05-27 |
| US20130156846A1 (en) | 2013-06-20 |
| EP2782566B1 (en) | 2021-01-06 |
| WO2013078395A1 (en) | 2013-05-30 |
| US20220000082A1 (en) | 2022-01-06 |
| US20180027781A1 (en) | 2018-02-01 |
| CA2855854C (en) | 2020-03-31 |
| AU2012340563A1 (en) | 2014-05-29 |
| US12295353B2 (en) | 2025-05-13 |
| US11974551B2 (en) | 2024-05-07 |
| CA2855854A1 (en) | 2013-05-30 |
| AU2012340563B2 (en) | 2017-01-19 |
| US11917986B2 (en) | 2024-03-05 |
| JP2014534263A (ja) | 2014-12-18 |
| IL232710B (en) | 2021-12-01 |
| ES2856063T3 (es) | 2021-09-27 |
| JP6265908B2 (ja) | 2018-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274469A (en) | Compositions, uses and methods for the treatment of metabolic disorders and diseases | |
| IL232710A0 (en) | l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders | |
| IL229257A0 (en) | Preparations and methods for the treatment of diseases related to the retina of the eye | |
| ZA201404676B (en) | Compositions and methods for treating metabolic disorders | |
| ZA201306038B (en) | New compositions for treating neurological disorders | |
| ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
| PT2726099T (pt) | Método para o tratamento de distúrbios metabólicos | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| EP2663653A2 (en) | Methods for diagnosing and treating eye-length related disorders | |
| ZA201500561B (en) | Compositions and treatment for eye diseases and disorders | |
| ZA201401438B (en) | Methods for treating cardiovascular disorders | |
| EP2611765A4 (en) | METHODS OF TREATING NEURODEGENERATIVE DISEASES | |
| IL231158A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| IL231157A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| IL228541A (en) | Compounds for the treatment of neurodegenerative disorders | |
| IL235317A0 (en) | A compound for the treatment of metabolic disorders | |
| TWI559917B (en) | Methods and compositions for treating neurodegenerative diseases | |
| AP2013007056A0 (en) | Methods and compositions for treating kidney disorders | |
| PL2691103T3 (pl) | Metoda leczenia zaburzeń skóry | |
| SG11201402899TA (en) | Methods and compositions for treating viral diseases | |
| EP2747765A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES | |
| AU2011903969A0 (en) | Compositions for treating skin conditions | |
| GB201101183D0 (en) | Treatment of neurodegenerative disorders | |
| IL213610A0 (en) | Composition for treating dermatological conditions |